Radiopharm Theranostics (ASX:RAD) has announced that the US FDA has granted Rare Pediatric Disease Designation for its DUNP19 technology for the treatment of osteosarcoma.
FDA grants important designation to Radiopharm Theranostics' DUNP19 technology
September 19, 2022 Australian Biotech
Latest Video
New Stories
-
PYC reports strong clinical momentum and cash position ahead of key readouts
October 27, 2025 - - Australian Biotech -
Government backs new national push to close bone health testing gap for women
October 27, 2025 - - Latest News -
Leadership change at PolyNovo as long-time Chair steps down
October 27, 2025 - - Australian Biotech -
Cann Group announces major debt restructure and capital raise to strengthen balance sheet
October 27, 2025 - - Australian Biotech -
FDA awards the first-ever national priority vouchers to nine sponsors
October 27, 2025 - - Latest News -
Cancer Australia looks to accelerate the delivery of national plan
October 27, 2025 - - Latest News -
Mark Butler announces the addition of another contraceptive option to the PBS
October 27, 2025 - - Latest News
